Illumina Inc.'s motion to amend its action against BGI Genomics Co. and others for infringement of its patent for labelled nucleotides was granted by a federal district court in California. Illumina sought to add a literal infringement theory that the CoolMPS product infringes its patent. The court determined that Illumina had good cause to amend its complaint, it acted with reasonable diligence in seeking leave to amend, and amendment would not unduly prejudice BGI.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.